Identification of the rat NKG2D ligands, RAE1L and RRLT, and their role in allograft rejection
✍ Scribed by Ming Zhuo; Masato Fujiki; Mouer Wang; Karine Piard-Ruster; Lu-En Wai; Liang Wei; Olivia M. Martinez; Sheri M. Krams
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 490 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
NKG2D is a receptor expressed by NK cells and subsets of T lymphocytes. On NK cells, NKG2D functions as a stimulatory receptor that induces effector functions. We cloned and expressed two rat NKG2D ligands, both members of the RAE1 family, RAE1L and RRLT, and demonstrate that these ligands can induce IFN‐γ secretion and cytotoxicity by rat NK cells. To examine changes in expression of NKG2D and the NKG2D ligands RAE1L and RRLT after transplantation, we used a Dark Agouti (DA)→Lewis rat model of liver transplantation. NKG2D expression was significantly increased in allogeneic liver grafts by day 7 post‐transplant. Ligands of NKG2D, absent in normal liver, were readily detected in both syngeneic and allogeneic liver grafts by day 1 post‐transplant. By day 7 post‐transplant, hepatocyte RAE1L and RRLT expression was significantly and specifically increased in liver allografts. In contrast to acute rejection that develops in the DA→Lewis model, transplantation of Lewis livers into DA recipients (Lewis→DA) results in spontaneous tolerance. Interestingly, expression of RAE1L and RRLT is low in Lewis→DA liver allografts, but significantly increased in DA→Lewis liver allografts undergoing rejection. In conclusion, our results suggest that expression of NKG2D ligands may be important in allograft rejection.
📜 SIMILAR VOLUMES
## Abstract Antibody‐dependent cellular cytotoxicity (ADCC) is a major antitumor mechanism of action of therapeutic monoclonal antibodies (mAbs). The aim of this study was to identify tumor‐associated factors which determine susceptibility to rituximab‐induced ADCC. Thirty different CD20+ non‐Hodgk